Can a drug stop kidney disease from returning after transplant?
NCT ID NCT02683889
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tested whether the drug Acthar can prevent focal segmental glomerulosclerosis (FSGS) from coming back in people who receive a kidney transplant. Fifteen adults with FSGS and advanced kidney disease took part. Researchers measured how many had FSGS return by looking at kidney biopsies and urine tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FSGS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medstar Georgetown Transplant Institute
Washington D.C., District of Columbia, 20005, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New biobank aims to unlock why kidney disease returns after transplant
- Personalized trial matching could revolutionize kidney disease treatment
- New drug aims to calm immune attacks on kidneys
- New study aims to measure swelling in kidney disease patients
- New kidney drug candidate SK-09 enters first human safety tests
- New hope for FSGS: experimental drug APL2 enters Late-Stage trial